Abstract
INTRODUCTION
This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p-tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer’s disease (AD).
METHODS
The diagnostic performance of the Lumipulse G plasma p-tau217/Aβ42 ratio was evaluated using Aβ and tau positron emission tomography (PET) as reference standards in a clinic cohort (n = 391) and a community cohort (n = 121).
RESULTS
Plasma p-tau217/Aβ42 exhibited high performance for abnormal statuses of Aβ PET (area under the curve [AUC]: 0.963 to 0.966) and tau PET (AUC: 0.947 to 0.974), which were clinically equivalent to those of cerebrospinal fluid (CSF) p-tau181/Aβ42 and Aβ42/Aβ40 and higher than those of blood p-tau217, Aβ42/Aβ40, p-tau181, and p-tau181/Aβ42 in both clinic and community cohorts. Applying a two-cutoff approach improved the specificity without reducing sensitivity. The p-tau217/Aβ42 ratio had a lower intermediate percentage than p-tau217 alone in both clinic (10.6% vs 13.0%) and community (16.5% vs 31.4%) cohorts.
DISCUSSION
Plasma p-tau217/Aβ42 has high performance in detecting cerebral AD pathologies, thus offering a promising tool for clinical diagnosis and community screening of AD.
Highlights
Lumipulse G plasma p-tau217 and the p-tau217/Aβ42 ratio accurately identified abnormal Aβ and tau PET statuses in both clinical and community cohorts.
The performance of plasma p-tau217 and p-tau217/Aβ42 ratio were equivalent to CSF tests.
Plasma p-tau217/Aβ42 ratio outperformed p-tau217 alone in identifying Aβ PET positivity, and this superiority is more obvious in the community cohort, suggesting an advantage in the early diagnosis of AD.
Two cut points of p-tau217/Aβ42 were established in the Chinese population for clinical laboratory and community screening uses.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Jun Wang,
Shan Huang,
Guoyu Lan,
Yu‐Jie Lai,
Qing‐Hua Wang,
Yang Chen,
Zhong‐Song Xiao,
Xiao Chen,
Xian‐Le Bu,
Yu‐Hui Liu,
Fan Zeng,
Laihong Zhang,
Anqi Li,
Yue Cai,
Pan Sun,
Zhengbo He,
Vincent Doré,
Jurgen Fripp,
Pierrick Bourgeat,
Qin Chen,
Jin‐Tai Yu,
Yi Tang,
Henrik Zetterberg,
Colin L. Masters,
Tengfei Guo,
Yan‐Jiang Wang,
for the Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN) | March 29, 2025